- Home
- AIO vs GYRE Comparison
AIO vs GYRE Comparison
Compare AIO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- GYRE
- Stock Information
- Founded
- AIO 2019
- GYRE 2002
- Country
- AIO United States
- GYRE United States
- Employees
- AIO N/A
- GYRE N/A
- Industry
- AIO Finance/Investors Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- AIO Finance
- GYRE Health Care
- Exchange
- AIO Nasdaq
- GYRE Nasdaq
- Market Cap
- AIO 826.9M
- GYRE 897.1M
- IPO Year
- AIO N/A
- GYRE N/A
- Fundamental
- Price
- AIO $23.41
- GYRE $8.07
- Analyst Decision
- AIO
- GYRE
- Analyst Count
- AIO 0
- GYRE 0
- Target Price
- AIO N/A
- GYRE N/A
- AVG Volume (30 Days)
- AIO 141.5K
- GYRE 412.5K
- Earning Date
- AIO 01-01-0001
- GYRE 08-12-2025
- Dividend Yield
- AIO 9.05%
- GYRE N/A
- EPS Growth
- AIO N/A
- GYRE N/A
- EPS
- AIO N/A
- GYRE 0.02
- Revenue
- AIO N/A
- GYRE $100,643,000.00
- Revenue This Year
- AIO N/A
- GYRE $21.04
- Revenue Next Year
- AIO N/A
- GYRE $89.64
- P/E Ratio
- AIO N/A
- GYRE $100.77
- Revenue Growth
- AIO N/A
- GYRE N/A
- 52 Week Low
- AIO $15.09
- GYRE $6.11
- 52 Week High
- AIO $20.25
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- AIO 51.01
- GYRE 43.87
- Support Level
- AIO $24.12
- GYRE $7.99
- Resistance Level
- AIO $24.67
- GYRE $8.55
- Average True Range (ATR)
- AIO 0.45
- GYRE 0.64
- MACD
- AIO -0.18
- GYRE -0.05
- Stochastic Oscillator
- AIO 6.49
- GYRE 28.82
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.